Thursday, March 31, 2022 SAVE: NIAID's 'Avengers-Like' Research Program for Evolving Pathogens Caption: This illustration shows the workflow for the various group experts.   When the next SARS-CoV-2 variant of concern emerges in the world, NIAID will call on SAVE – its version of The Avengers – to quickly react and protect people. SAVE (SARS-CoV-2 Assessment of Viral Evolution) members assess whether mutations in variants can affect virus transmission, severity and immunity; test vaccines and therapeutics; and guide responses. Like the comic book heroes fighting various mutant threats, SAVE focuses on mutations in SARS-CoV-2 and emerging virus variants. Program members say the global collaborative concept is a broad model for rapidly responding to evolving pathogens with pandemic potential. NIAID assembled and coordinated SAVE scientists in January 2021, drawing on experts from around the world who specialize in relevant research fields such as viruses, the immune system, vaccines, epidemiology, structural biology, bioinformatics, virus genetics, and evolution. SAVE members represent 58 different research sites located in the United States and around the world. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107